AbbVie (NYSE:ABBV) Downgraded to “Hold” Rating by DZ Bank

AbbVie (NYSE:ABBV) was downgraded by equities research analysts at DZ Bank from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday, MarketBeat Ratings reports. They currently have a $237.00 price target on the stock. DZ Bank’s price target points to a potential upside of 11.77% from the company’s current price.

A number of other research analysts have also weighed in on the company. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a report on Wednesday, October 8th. Wells Fargo & Company boosted their target price on AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a report on Friday, September 12th. UBS Group set a $251.00 target price on AbbVie in a report on Friday, October 3rd. HSBC set a $225.00 target price on AbbVie in a report on Thursday, October 2nd. Finally, Guggenheim upped their price objective on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a report on Monday, October 20th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat, AbbVie has an average rating of “Moderate Buy” and a consensus price target of $237.81.

AbbVie Stock Down 2.8%

NYSE:ABBV opened at $212.04 on Tuesday. The firm has a market capitalization of $374.58 billion, a price-to-earnings ratio of 100.97, a price-to-earnings-growth ratio of 1.42 and a beta of 0.51. AbbVie has a twelve month low of $163.81 and a twelve month high of $244.81. The stock’s 50 day moving average price is $222.51 and its two-hundred day moving average price is $201.42. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The firm’s revenue was up 9.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities research analysts expect that AbbVie will post 12.31 earnings per share for the current fiscal year.

Insider Buying and Selling at AbbVie

In other news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the company’s stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the completion of the sale, the executive vice president directly owned 177,292 shares in the company, valued at approximately $35,178,278.64. This represents a 19.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.25% of the company’s stock.

Institutional Trading of AbbVie

Institutional investors have recently modified their holdings of the stock. Marshall & Sullivan Inc. WA bought a new stake in shares of AbbVie during the 2nd quarter valued at $25,000. Evolution Wealth Management Inc. bought a new stake in shares of AbbVie during the 2nd quarter valued at $26,000. TD Capital Management LLC lifted its position in shares of AbbVie by 82.9% during the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after buying an additional 58 shares during the last quarter. Spurstone Advisory Services LLC bought a new stake in shares of AbbVie during the 2nd quarter worth $28,000. Finally, Abound Financial LLC bought a new stake in shares of AbbVie during the 1st quarter worth $30,000. 70.23% of the stock is currently owned by institutional investors.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.